Coherus (CHRS) CEO Lanfear has 11,839 shares withheld for RSU taxes

Rhea-AI Filing Summary

Coherus Oncology President & CEO Dennis M. Lanfear reported an automatic share withholding related to equity compensation. On January 20, 2026, the issuer withheld 11,839 shares of common stock at $1.55 per share to cover taxes due on the vesting of restricted stock units, and no shares were sold by Lanfear in this transaction. After this withholding, he beneficially owned 673,235 shares directly, plus 432,684 shares held by the Lanfear Revocable Trust and 86,965 shares held by Lanfear Capital Advisors, LLC, both entities associated with him.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Lanfear Dennis M

Role President & CEO

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	11,839	$1.55	$18K
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 673,235 shares (Direct); Common Stock — 432,684 shares (Indirect, By Trust)

Footnotes (1)

1. Represents shares automatically withheld by the Issuer to pay related tax liability in connection with the vesting of restricted stock units in accordance with Rule 16b-3. No shares were sold by the Reporting Person in connection with the foregoing transaction. These shares are held by the Lanfear Revocable Trust, dated January 27, 2004, as restated, of which Reporting Person is a trustee. These shares are held by Lanfear Capital Advisors, LLC of which Reporting Person is President.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lanfear Dennis M

(Last) (First) (Middle)

C/O COHERUS ONCOLOGY, INC.

333 TWIN DOLPHIN DRIVE, SUITE 600

(Street)

REDWOOD CITY CA 94065

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Coherus Oncology, Inc. [ CHRS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & CEO

3. Date of Earliest Transaction (Month/Day/Year)
01/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/20/2026		F		11,839(1)	D	$1.55	673,235	D
Common Stock								432,684	I	By Trust(2)
Common Stock								86,965	I	By LLC(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares automatically withheld by the Issuer to pay related tax liability in connection with the vesting of restricted stock units in accordance with Rule 16b-3. No shares were sold by the Reporting Person in connection with the foregoing transaction.

2. These shares are held by the Lanfear Revocable Trust, dated January 27, 2004, as restated, of which Reporting Person is a trustee.

3. These shares are held by Lanfear Capital Advisors, LLC of which Reporting Person is President.

	/s/ Bryan McMichael, as Attorney-in-Fact for Dennis M. Lanfear	01/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Coherus Oncology (CHRS) report for Dennis M. Lanfear?

The filing reports that on January 20, 2026, the issuer automatically withheld 11,839 shares of Coherus Oncology common stock at $1.55 per share to cover tax liabilities from the vesting of restricted stock units for President & CEO Dennis M. Lanfear.

Did Dennis M. Lanfear sell Coherus Oncology (CHRS) shares in this Form 4?

No. The filing states that the 11,839 shares were automatically withheld by the issuer to pay related tax liability in connection with restricted stock unit vesting, and that no shares were sold by Lanfear in this transaction.

How many Coherus Oncology (CHRS) shares does Dennis M. Lanfear own directly after the reported transaction?

Following the withholding transaction, Dennis M. Lanfear directly beneficially owned 673,235 shares of Coherus Oncology common stock.

What indirect Coherus Oncology (CHRS) holdings are associated with Dennis M. Lanfear?

The filing lists 432,684 shares held by the Lanfear Revocable Trust, where he is a trustee, and 86,965 shares held by Lanfear Capital Advisors, LLC, where he is President, as indirect beneficial holdings.

What does transaction code "F" mean in the Coherus Oncology (CHRS) Form 4?

Transaction code "F" indicates shares were withheld by the issuer to pay tax obligations linked to equity awards, in this case the vesting of restricted stock units, rather than an open-market purchase or sale.

What role does Dennis M. Lanfear hold at Coherus Oncology (CHRS)?

Dennis M. Lanfear is identified as a Director and the President & CEO of Coherus Oncology, Inc. in the Form 4 filing.